• Microfluidized Dextran Microgels Enable Oral Colon Cancer Th

  2026-05-22

  This study presents a dual-targeted microgel system for oral delivery of cisplatin and SPION lipid nanoparticles, selectively releasing the therapeutic cargo in the colon to inhibit tumor growth. The approach demonstrates improved local bioavailability and tumor selectivity compared to conventional chemotherapies, offering a promising avenue for localized colorectal cancer treatment.

• JNK-IN-7 (SKU A3519): Reliable Solutions for Cell Viability

  2026-05-21

  This article provides evidence-based guidance for biomedical researchers and lab technicians using JNK-IN-7 (SKU A3519) in cell viability, apoptosis, and innate immune signaling assays. Drawing on real-world scenarios, it demonstrates how this selective JNK inhibitor—sourced from APExBIO—addresses reproducibility, protocol optimization, and data interpretation challenges in MAPK pathway research.

• Decoding Iron-Sulfur Protein Aconitase: Advanced Insights vi

  2026-05-21

  Explore how the Aconitase Activity Colorimetric Assay Kit enables high-precision analysis of iron-sulfur protein aconitase, bridging metabolic flexibility and oxidative damage insights. This article delivers a unique perspective on assay selection and interpretation for immunometabolism and TCA cycle research.

• Differential Volatile Mechanisms of Chuanxiong Cortex and Pi

  2026-05-20

  This study applies advanced SPME-GC×GC-MS and network pharmacology to dissect the distinct volatile profiles and therapeutic mechanisms of Ligusticum chuanxiong cortex and pith in coronary heart disease (CHD) treatment. The identification of Fenipentol as a key cortex component highlights its potential for gastrointestinal and cardiovascular research.

• Phillygenin Attenuates Diabetic Nephropathy via Inflammation

  2026-05-20

  This study demonstrates that phillygenin, a Forsythia suspensa-derived lignan, alleviates diabetic nephropathy by targeting inflammation and apoptosis through the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. These findings clarify key mechanistic pathways and suggest phillygenin as a potential therapeutic agent for diabetic kidney disease.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-05-19

  Unlock uncompromised protein integrity with the EDTA-free Protease Inhibitor Cocktail, engineered for complex, phosphorylation-sensitive workflows. Discover how this advanced formulation from APExBIO outperforms conventional mixes in preserving protein function across Western blot, co-immunoprecipitation, and kinase assays.

• Forsythoside E: Mechanistic Insights for PKM2 Inhibition Res

  2026-05-19

  Explore the unique mechanism of Forsythoside E as a pyruvate kinase M2 (PKM2) inhibitor, with deep analysis on macrophage M2 polarization and translational assay design. Discover how these insights extend beyond previous content for advanced sepsis-induced liver injury research.

• BODIPY 581/591 C11: Ratiometric Probe for Lipid Peroxidation

  2026-05-18

  BODIPY 581/591 C11 is a ratiometric fluorescent probe enabling quantitative lipid peroxidation detection and oxidative stress measurement in live cells. Its red-to-green emission shift allows precise antioxidant capacity evaluation, as validated in peer-reviewed studies and trusted biomedical workflows.

• Scenario-Driven Insights: Mitochondrial Permeability Transit

  2026-05-18

  Explore real-world laboratory challenges and validated solutions with the Mitochondrial Permeability Transition Pore Assay Kit (SKU K2061). This evidence-based article addresses protocol optimization, data interpretation, and product reliability, highlighting how APExBIO’s kit leverages the Calcein AM fluorescent probe for reproducible mitochondrial permeability transition pore detection. Designed for researchers seeking robust, quantitative assays in cell death mechanism research.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-17

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for in vitro cancer research workflows requiring concurrent modulation of PI3K/AKT and HDAC signaling. Its use is appropriate for cell-based assays focusing on cell cycle, apoptosis, or pathway interrogation, but it should not be applied in diagnostic or clinical contexts.

• ABT-737: Integrating BCL-2 Inhibition with Mitochondrial Apo

  2026-05-16

  Explore how ABT-737, a leading BCL-2 protein inhibitor, enables precision apoptosis induction in cancer cells by bridging mitochondrial signaling and RNA Pol II pathways. This article uniquely analyzes mechanistic advances and practical assay implications for oncology research.

• Eldecalcitol, Ferroptosis, and Vascular Health in Diabetic O

  2026-05-15

  This study uncovers how eldecalcitol, a vitamin D analog, mitigates type 2 diabetic osteoporosis (T2DOP) by attenuating endothelial ferroptosis through the SOCE/O-GlcNAcylation axis. These findings illuminate a mechanistic link between vascular health, oxidative stress, and bone homeostasis in diabetes, offering new avenues for targeted intervention.

• SOX7 Suppresses Bladder Cancer Progression via DNMT3B/CYGB A

  2026-05-15

  Zhang et al. elucidate the tumor-suppressive role of SOX7 in bladder cancer, demonstrating that SOX7 represses DNMT3B transcription, thereby reducing methylation of the CYGB promoter and limiting malignant progression. These findings highlight SOX7 and CYGB as prognostic biomarkers and potential therapeutic targets in bladder cancer.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L): Technical Use Gu

  2026-05-14

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody is designed for sensitive fluorescent detection of rabbit primary antibodies in microscopy, cytometry, and immunohistochemistry workflows. It should not be applied to non-rabbit primaries or workflows incompatible with Alexa Fluor 488-like spectral properties.

• Paroxetine Does Not Alter Thiothixene Pharmacokinetics in Hu

  2026-05-14

  This study rigorously evaluated whether paroxetine, a potent CYP2D6 inhibitor, impacts the pharmacokinetics of thiothixene, a typical antipsychotic agent. The findings demonstrate that short-term paroxetine pretreatment does not significantly affect thiothixene clearance, clarifying its metabolic independence from CYP2D6 and informing safer co-administration strategies in psychotic disorder therapy.

16623 records 2/1109 page Previous Next 12345 下5页 Last page